Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

Exclusion Criteria

• •Patients who had failed 2 or more prior systemic treatments for AD.
• •Patients who had received a live or attenuated vaccine in the last 12 weeks or intend to receive a live or attenuated vaccine during the study.
• •Patients who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study.
• •Has unstable AD, based on the judgement of the Investigator, or any consistent requirement for high potency topical steroids to manage AD signs or symptoms.
• •Patients who had significant active systemic or localized bacterial, viral, fungal, and helminth infection in the last 30 days.
• •Patients unwilling to refrain from prolonged sun exposure or use of a tanning bed or other artificial light emitting devices for 4 weeks prior to Baseline and during the study.
• •Patients with other skin conditions that would interfere with evaluations of the effect of the study medication on AD, as determined by the Investigator.
• •Patients with known genetic dermatological conditions that overlap with AD, such as Netherton syndrome.
• •Previous used of a BTK inhibitor.
• •Women who were pregnant, wishing to become pregnant during the study, or were breastfeeding.
• •Patients were undergoing allergy (eg, food allergy testing or skin prick testing), patch testing, or food challenges, or plan to do so during the study.
• •Patients who had undergone major surgery within 4 weeks prior to Day 1 or patients who had a major surgery planned during the study.
• •Regular use of drugs of abuse or regular alcohol consumption within 6 months prior to the study.